Kaiser Permanente- Modesto MOB II

Futó vizsgálatok

• Toboroz

  Testing Short-Course Radiation Versus Standard-Course Radiation for Soft Tissue Sarcomas That Need Surgery and Radiation

  NCT07615049· 3. fázis· Forrás

• Toboroz

  Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

  NCT07215910· 3. fázis· Forrás

• Toboroz

  Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

  NCT07321652· 3. fázis· Forrás

• Toboroz

  Distance-Based Exercise to Preserve Function and Prevent Disability

  NCT07059884· Forrás

• Toboroz

  Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  NCT07198074· 3. fázis· Forrás

• Toboroz

  Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

  NCT06931340· 3. fázis· Forrás

• Toboroz

  High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

  NCT06992427· 3. fázis· Forrás

• Toboroz

  Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  NCT06498635· 3. fázis· Forrás

• Toboroz

  Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  NCT06580314· 3. fázis· Forrás

• Toboroz

  Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  NCT06418204· Forrás

• Fut, nem toboroz

  Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

  NCT06632327· 3. fázis· Forrás

• Toboroz

  Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  NCT06317649· 2. fázis· Forrás

• Toboroz

  Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

  NCT06422806· 3. fázis· Forrás

• Toboroz

  Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

  NCT06096844· 3. fázis· Forrás

• Toboroz

  Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

  NCT06203600· 2/3. fázis· Forrás

• Toboroz

  MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  NCT05564390· 2. fázis· Forrás

• Toboroz

  Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

  NCT05987241· 2/3. fázis· Forrás

• Toboroz

  Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

  NCT05946213· 3. fázis· Forrás

• Toboroz

  Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  NCT05879926· 3. fázis· Forrás

• Toboroz

  Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

  NCT05812807· 3. fázis· Forrás

• Toboroz

  mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

  NCT05677490· 3. fázis· Forrás

• Toboroz

  Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

  NCT05174169· 2/3. fázis· Forrás

• Fut, nem toboroz

  Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

  NCT05095376· 3. fázis· Forrás

• Fut, nem toboroz

  Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

  NCT05050084· 3. fázis· Forrás

• Toboroz

  Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

  NCT04181060· 3. fázis· Forrás

• Toboroz

  A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

  NCT04251052· Forrás

• Toboroz

  Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  NCT04267848· 3. fázis· Forrás

• Toboroz

  Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  NCT03150693· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák5 toboroz
• Petefészekrák4 toboroz
• Gyomor- és nyelőcsőrák3 toboroz
• Prosztatarák3 toboroz
• Szarkóma3 toboroz
• Vastagbélrák3 toboroz
• Akut mieloid leukémia (AML)2 toboroz
• Hólyagrák2 toboroz
• Méhtestrák2 toboroz
• Akut limfoid leukémia (ALL)1 toboroz
• Fej-nyaki daganatok1 toboroz
• Gyermekkori daganatok1 toboroz
• Hasnyálmirigyrák1 toboroz
• Krónikus limfoid leukémia (CLL)1 toboroz
• Máj- és epeúti rák1 toboroz
• Méhnyakrák1 toboroz
• Melanóma1 toboroz
• Mielodiszplasztikus szindróma (MDS)1 toboroz
• Mieloproliferatív neopláziák1 toboroz
• Tripla negatív emlőrák1 toboroz
• Vesedaganat1 toboroz

Kutatók

Ide még nem kötődik kutató.